San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

Ten years after her sexual assault, she discovered that the evidence in her rape kit hadn’t been tested — and neither had ...

for the treatment of Amyotrophic Lateral Sclerosis (ALS). The European Commission is scheduled to issue the official decision on the Orphan Designation in December. OMPD will offer Neurizon a range of ...

John Rzeznik, Brian Fallon, Pete Steinkopf, Dramarama, Willie Nile, Joe Grushecky and the Houserockers and more set for Bob's ...

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage ...

The FDA initially halted the trials on 16 October after a patient in the Phase II trial (NCT05519839) of the CIC vaccine ...

Scientists are working on a way to restore the production of a protein that is essential for communication in the brain and ...

The condition is a rapidly progressive neurodegenerative disorder leading to wasting, paralysis and eventual death from ...

Amyotrophic lateral sclerosis (ALS) is the most common form of MND and there is currently no cure for the condition which ...